Clinical trials: Relapsed /Refractory Acute Myeloid Leukemia
Recurrent Adult Acute Myeloid Leukemia, Refractory Acute Myeloid Leukemia
Donor Natural Killer Cells in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia
This phase I/II trial studies the side effects and best dose of donor natural kill cells and to see how well they work in treating patients with acute myeloid leukemia that does not respond to treatment (refractory) or has come…
- Trial name
- NCT01787474
- Testing
- Cytarabine, Filgrastim, Filgrastim-sndz
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- M.D. Anderson Cancer Center
Acute Myeloid Leukemia, Relapse Leukemia
Cladribine in Combination With CAG in Patients With Refractory/Relapsed Acute Myeloid Leukemia
The vast majority of patients with AML will die of the disease, and no standard chemotherapy regimen were defined for patients with relapsed/refractory AML.
- Trial name
- NCT03181815
- Testing
- Cladribine, G-CSF, Aclarubicin
- Where
- China
- Volunteers
- 48 people
- Sponsor
- Sun Yat-sen University
Adult Acute Basophilic Leukemia, Adult Acute Eosinophilic Leukemia
XK469R in Treating Patients With Refractory Hematologic Cancer
Phase I trial to study the effectiveness of XK469R in treating patients who have refractory hematologic cancer. Drugs used in chemotherapy, such XK469R, work in different ways to stop cancer cells from dividing so they stop…
- Conditions
- Adult Acute Basophilic Leukemia, Adult Acute Eosinophilic Leukemia, Adult Acute Megakaryoblastic Leukemia (M7), Adult Acute Minimally Differentiated Myeloid Leukemia (M0)
- Trial name
- NCT00095797
- Testing
- R(+)XK469, pharmacological study, laboratory biomarker analysis
- Where
- United States
- Volunteers
- 60 people
- Sponsor
- National Cancer Institute (NCI)
Accelerated Phase Chronic Myelogenous Leukemia, Acute Undifferentiated Leukemia
Massage Therapy Given by Caregiver in Treating Quality of Life of Young Patients Undergoing Treatment for Cancer
This clinical trial studies massage therapy given by caregiver in treating quality of life of young patients undergoing treatment for cancer.
- Conditions
- Accelerated Phase Chronic Myelogenous Leukemia, Acute Undifferentiated Leukemia, Angioimmunoblastic T-cell Lymphoma, Atypical Chronic Myeloid Leukemia, BCR-ABL1 Negative
- Trial name
- NCT01053494
- Testing
- massage therapy, questionnaire administration, quality-of-life assessment
- Where
- United States
- Volunteers
- 80 people
- Sponsor
- Wake Forest University Health Sciences
Acute Myeloid Leukemia
Cytokine-Induced Memory-Like Natural Killer Cells (CIML-NK) for Relapsed & Refractory Acute Myeloid Leukemia (AML)
The objective of this study is to demonstrate that cytokine-induced memory-like natural killer cells can be generated from donor cells and infused safely into patients with relapsed or refractory acute myeloid leukemia (AML).
- Trial name
- NCT05580601
- Testing
- CIML-NK Cells
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Children's Hospital Medical Center, Cincinnati
Leukemia, Lymphoma
Chemotherapy Given With Amifostine and Filgrastim in Treating Patients With Recurrent or Metastatic Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Chemoprotective drugs such as amifostine may protect normal cells from the side effects of chemotherapy.
- Conditions
- Leukemia, Lymphoma, Unspecified Adult Solid Tumor, Protocol Specific
- Trial name
- NCT00003294
- Testing
- filgrastim, amifostine trihydrate, carboplatin
- Where
- United States
- Volunteers
- 24 people
- Sponsor
- Roswell Park Cancer Institute
Relapsed or Refractory Acute Myeloid Leukemia
Venetoclax, Chidamide, and Chiglitazar Sodium (VCC) in Patients With Relapsed/Refractory Acute Myeloid Leukemia
To evaluate the efficacy and safety of venetoclax, chidamide, and chiglitazar sodium (VCC) in patients with relapsed or refractory acute myeloid leukemia (R/R AML).
- Trial name
- NCT07783100
- Testing
- venetoclax, chidamide, and chiglitazar sodium (VCC)
- Where
- China
- Volunteers
- 30 people
- Sponsor
- The First Affiliated Hospital of Xiamen University
AML, MDS
Combination Salvage Therapy With Venetoclax and Decitabine in Relapsed/Refractory AML
The goal of this prospective, phase II single center, one arm, open label clinical trial is to test the efficacy and feasibility of a combination salvage therapy with Venetoclax and intensified Decitabine in patients with newly…
- Trial name
- VenSwitch (NCT06156579)
- Testing
- Decitabine, Venetoclax
- Where
- Germany
- Volunteers
- 27 people
- Sponsor
- University Hospital Tuebingen
Leukemia, Lymphoma
Chemotherapy Plus Donor White Blood Cell Infusion in Treating Patients With Relapsed Hematologic Cancer Following Donor Peripheral Stem Cell Transplantation
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. White blood cells from donors may be able to prevent graft-versus-host disease in patients with hematologic…
- Conditions
- Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm, Myelodysplastic Syndromes
- Trial name
- NCT00005946
- Testing
- filgrastim, therapeutic allogeneic lymphocytes, cyclophosphamide
- Where
- United States
- Sponsor
- University of Maryland, Baltimore
Acute Myeloid Leukemia
iCare4: Genomic Signatures With Midostaurin in Acute Myeloid Leukemia (UF-HEM-004)
This is an open label, single arm study of midostaurin in patients with relapsed or refractory AML.
- Trial name
- NCT03207334
- Testing
- Midostaurin, Cytarabine
- Where
- United States
- Sponsor
- University of Florida
Acute Myelogenous Leukemia, Myelodysplastic Syndromes
Clofarabine and Ara-C for the Treatment of Relapsed AML and Untreated MDS
The purpose of this trial is to to determine the safety and effectiveness of therapeutic combination - Clofarabine and Cytarabine for the treatment of AML and MDS.
- Conditions
- Acute Myelogenous Leukemia, Myelodysplastic Syndromes, Chronic Myelogenous Leukemia
- Trial name
- NCT00334074
- Testing
- Clofarabine and Cytarabine
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- Baylor Research Institute
Acute Myeloid Leukemia (AML)
Selinexor in Combination With Fludarabine and Cytarabine in Patients With Refractory or Relapsed Acute Myeloid Leukemia
This study will be done in two parts: Phase I (NCT02212561) has been completed and published. The goal of the Phase I portion of this study was to find the highest tolerable dose of selinexor (KPT-330) that can be given to…
- Trial name
- NCT03071276
- Testing
- Selinexor, Fludarabine, Cytarabine
- Where
- 7 sites in United States
- Volunteers
- 37 people
- Sponsor
- St. Jude Children's Research Hospital
Relapsed Adult AML
Study of Oral PCLX-001 in R/R Acute Myeloid Leukemia
This is a dose-finding study of oral zelenirstat (PCLX-001) in patients with R/R AML. There are two parts to the study: Dose Escalation and Dose Expansion.
- Trial name
- NCT06613217
- Testing
- zelenirstat
- Where
- United States
- Volunteers
- 35 people
- Sponsor
- Pacylex Pharmaceuticals
Multiple Myeloma, Acute Myeloid Leukemia
A Study of PRT1419 in Patients With Relapsed/Refractory Hematologic Malignancies
This is a Phase 1 dose-escalation study of PRT1419, a myeloid cell leukemia 1 (MCL1) inhibitor, in patients with relapsed/refractory hematologic malignancies.
- Conditions
- Multiple Myeloma, Acute Myeloid Leukemia, Non Hodgkin Lymphoma, Myelodysplastic Syndromes
- Trial name
- NCT04543305
- Testing
- PRT1419
- Where
- 5 sites in United States
- Volunteers
- 16 people
- Sponsor
- Prelude Therapeutics Incorporated
Leukemia, Lymphoma
Interleukin-2 Following Bone Marrow Transplantation in Treating Patients With Hematologic Cancer
RATIONALE: Interleukin-2 may stimulate a person's white blood cells to kill cancer cells. PURPOSE: Phase I trial to study the effectiveness of interleukin-2 following bone marrow transplantation in treating patients who have…
- Conditions
- Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm
- Trial name
- NCT00003962
- Testing
- aldesleukin
- Where
- United States
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Recurrent Acute Myeloid Leukemia, Refractory Acute Myeloid Leukemia
TK216 and Decitabine in Treating Patients With Relapsed and Refractory Acute Myeloid Leukemia
This phase I trial studies the side effects and best dose of TK216 and decitabine when given together in treating patients with acute myeloid leukemia that has come back or does not respond to treatment.
- Trial name
- NCT03752138
- Testing
- Group 1: TK216, Group 2: TK216, Part 2: Decitabine 10mg/m2
- Sponsor
- M.D. Anderson Cancer Center
Blasts More Than 20 Percent of Bone Marrow Nucleated Cells, Blasts More Than 20 Percent of Peripheral Blood White Cells
Ruxolitinib Phosphate and Decitabine in Treating Patients With Relapsed or Refractory or Post Myeloproliferative Acute Myeloid Leukemia
This phase I/II trial studies the side effects and best dose of ruxolitinib phosphate when given together with decitabine and to see how well they work in treating patients with acute myeloid leukemia that has come back or is not…
- Conditions
- Blasts More Than 20 Percent of Bone Marrow Nucleated Cells, Blasts More Than 20 Percent of Peripheral Blood White Cells, Myelodysplastic/Myeloproliferative Neoplasm, Recurrent Acute Myeloid Leukemia
- Trial name
- NCT02257138
- Testing
- Decitabine, Laboratory Biomarker Analysis, Ruxolitinib Phosphate
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- M.D. Anderson Cancer Center
Relapsed Acute Myeloid Leukemia, Refractory Acute Myeloid Leukemia
Influence of Molecular Abnormalities on Response of VAH vs. VEN+HMA in RR-AML
The aim of this study is to reveal the influence of gene mutations on the treatment response of the regimen of HHT combined with Venetoclax plus AZA versus venetoclax plus HMA in the salvage therapy of RR-AML.
- Conditions
- Relapsed Acute Myeloid Leukemia, Refractory Acute Myeloid Leukemia, Gene Abnormality, Cytogenetic Abnormality
- Trial name
- NCT05456048
- Testing
- VAH regimen, VEN+HMA regimen
- Where
- China
- Volunteers
- 231 people
- Sponsor
- Nanfang Hospital, Southern Medical University
Previously Untreated Relapsed Refractory Acute Myeloid Leukemia
Study of Biomarker-Based Treatment of Acute Myeloid Leukemia
This screening and multi-sub-study Phase 1b/2/3 trial will establish a method for genomic screening followed by assigning and accruing simultaneously to a multi-study "Master Protocol (BAML-16-001-M1)." The specific subtype of…
- Trial name
- NCT03013998
- Testing
- Samalizumab (BAML-16-001-S1), BI 836858 (BAML-16-001-S2), Laboratory Biomarker Analysis
- Where
- 31 sites in United States
- Volunteers
- 3,000 people
- Sponsor
- Beat AML, LLC
Acute Myeloid Leukemia
Cladribine Venetoclax in Monocytic AML
Investigation of Relapsed or refractory AML with a monocytic phenotype after failure of hypomethylating agent+venetoclax
- Trial name
- NCT06232655
- Testing
- Cladribine, Venetoclax, Azacitidine
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- University of Colorado, Denver